Notice of Results

    RNS Number : 0657V
  Celsis International PLC
  02 June 2008
   

    CELSIS INTERNATIONAL PLC
    NOTIFICATION OF RESULTS

    2 June 2008: Celsis International plc, the life sciences products and laboratory services company, will announce its preliminary results
for the year ended 31 March 2008 on Wednesday 18 June 2008.

    There will be a presentation to analysts on the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings,
London, WC2A 1PB.  There will also be a conference call available, for more information please contact Claire Rowell on [phone]
7285.

 Enquiries:

 Celsis International plc                 Tel: [phone]
 Jay LeCoque, Chief Executive Officer
 Jenny Woolway, Corporate Communications

 Financial Dynamics                       Tel: [phone]
 Lara Mott
 Ben Atwell

    Notes to editors
    Celsis International plc
    Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical,
biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development
services and ADME-Tox in vitro technologies.  The company is listed on the London Stock Exchange (CEL.L)

    Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to
ensuring product quality and safety for consumers.  Celsis Rapid Detection division utilises proprietary enzyme technology to develop and
supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer
products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in
process and finished goods to market.  Celsis Analytical Services division provides cost effective outsourced laboratory testing services to
pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug
development and discovery to analytical chemistry and biological sciences to stability storage and testing.  Celsis In Vitro Technologies
(Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries.  Celsis IVT's
consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost
of further development or trial on those compounds which will not be properly metabolised by the human liver.

    Further information can be found on its website at www.celsis.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NORGGGZKGZNGRZM